세계의 혈관성형술용 풍선 시장 예측(-2030년) : 유형별, 재료별, 적응증별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Angioplasty Balloons Market is accounted for $2.5 billion in 2023 and is expected to reach $3.7 billion by 2030 growing at a CAGR of 5.9% during the forecast period. The angioplasty balloons market has been driven in large part by the increasing prevalence of cardiovascular illnesses, including peripheral artery disease and coronary artery disease. When treating artery blockages, these balloons are essential and the safety and effectiveness of angioplasty balloons have been improved by ongoing developments in the field, including the use of drug-coated balloons (DCB), scoring balloons, and better materials.

According to the Journal of the American College of Cardiology published in February 2023, the incidence rate of atherosclerotic cardiovascular disease per 1,000 person-years was 2.60 among those with raised 10-year predicted risk, 1.87 in those with low 10-year but elevated 30-year predicted risk and 0.32 in those with low 10-year and 30-year predicted risk.

Market Dynamics:

Driver:

Increasing prevalence of cardiovascular diseases

The necessity for procedures such as angioplasty develops in tandem with the global growth in the incidence of cardiovascular illnesses. An essential part of these treatments are angioplasty balloons, which are used to unblock constricted or obstructed arteries and restore blood flow. Because more angioplasty balloons are needed by healthcare institutions and providers to meet patient demands, the market is expected to develop as a result of the growing demand for angioplasty treatments.

Restraint:

High cost

Exorbitant expenses may restrict patients' access to sophisticated or customized balloon angioplasty treatments. Market penetration may be impacted by obstacles that patients in areas with little financial resources or insufficient insurance coverage may have when trying to access these services. Problems with affordability might result in market segmentation, when patients or medical professionals choose more affordable options or conventional balloon angioplasty techniques over more advanced, costly ones.

Opportunity:

Quick adoption of advanced technologies

Innovation in angioplasty balloon design and production is stimulated by the rapid adoption of sophisticated technology. In order to produce more sophisticated and useful balloons, such as those with coatings that are drug-coated, scored, or made of unique materials and coatings, it incentivizes businesses to spend money on research and development. Businesses with a competitive edge are those who develop and successfully incorporate cutting-edge technologies into their angioplasty balloons. By providing creative solutions that meet unmet demands in the industry, these businesses would be able to take a bigger chunk of the market

Threat:

Complications associated with angioplasty

The risks of thrombosis, dissection, or artery damage related to angioplasty operations may cause medical professionals to become less confident in their use of angioplasty balloons. This might result in a more circumspect approach or lower rates of these gadgets being adopted. Moreover, complicated cases may be subject to more stringent regulatory monitoring or carry out more thorough assessments, which could cause the clearance process for novel angioplasty balloon technology to lag.

COVID-19 Impact

Many hospitals and healthcare facilities around the world delayed elective operations, including non-urgent angioplasty procedures, during the early stages of the pandemic. In order to protect resources, reduce patient exposure to the virus, and provide priority to COVID-19 patients, this was done. Patients visited hospitals and clinics less frequently because to lockdown procedures and fear of infection, which decreased the amount of cardiovascular disease diagnoses and angioplasty procedures that followed thus hampered the growth of the market.

The drug eluting balloons segment is expected to be the largest during the forecast period

The drug eluting balloons segment is estimated to have a lucrative growth, because using drug-eluting balloons is primarily intended to decrease the incidence of restenosis, which is the re-narrowing of the angioplasty-treated artery. The medication coating lessens the chance that the artery may constrict again by preventing the proliferation of cells in the arterial wall. Drug-eluting balloons have become popular and well-liked by interventional cardiologists as a viable therapeutic option, particularly in situations where stent placement may not be optimal or in narrow veins where stent deployment may be difficult.

The polyurethane segment is expected to have the highest CAGR during the forecast period

The polyurethane segment is anticipated to witness the highest CAGR growth during the forecast period, because of its elasticity and durability, polyurethane is a good material to employ in medical devices that need to be strong and flexible. Polyurethane angioplasty balloons can be designed with regulated inflation and deflation characteristics, enabling accurate artery dilatation throughout the treatment. With their unique material qualities, polyurethane angioplasty balloons remain a viable option within the larger angioplasty devices market.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the aging population, poor diets, increased obesity rates, and changes in lifestyle in the Asia Pacific region. The number of CVD cases has increased, which has raised demand for interventional cardiology treatments like angioplasty. The safety and effectiveness of medical devices are guaranteed by the various regulatory frameworks that each nation in the area has for them. In order to market their products in their different countries, manufacturers must adhere to certain restrictions.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period; owing to the considerable increasing interventional cardiology equipment. Moreover, Europe was seeing an increase in the prevalence of cardiovascular disorders, which was driving demand for these devices and the constant progress in balloon composition, drug-coated balloons, and imaging technology was improving angioplasty operations' efficacy and safety. Novelties like bioresorbable scaffolds and drug-eluting balloons were becoming more popular which drives the growth of the market.

Key players in the market:

Some of the key players profiled in the Angioplasty Balloons Market include Boston Scientific Corporation, Medtronic, Johnson & Johnson Services, Inc., Abbott, Cardinal Health, Terumo Medical Corporation, B. Braun Melsungen AG, ENDOCOR GmbH, BIOTRONIK, Cook, Spectranetics, C. R. Bard, Inc., AngioDynamics, Becton Dickinson, Biomerics, INFINITY Angioplasty Balloon, MicroPort Scientific Corporation, Nipro Medical Corporation., Hexacath and CTK biotech, Inc

Key Developments:

In November 2023, Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept

In November 2023, Medtronic announces FDA approval of minimally invasive device to treat hypertension. Approval is the culmination of ten years of clinical research and development of the Medtronic renal denervation technology

In September 2023, Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device. The WATCHMAN FLX Pro device is built upon the proven safety and procedural performance

Types Covered:

• Drug Eluting Balloons
• Normal Balloons
• Cutting Balloons
• Scoring Balloons
• Other Types

Materials Covered:

• Polyurethane
• Silicone Urethane Co-Polymers
• Nylon
• Other Materials

Indications Covered:

• Angioplasty
• Renal Artery Angioplasty
• Peripheral Angioplasty
• Carotid Angioplasty
• Venous Angioplasty
• Coronary Angioplasty
• Other Indications

End Users Covered:

• Ambulatory Surgical Centers
• Hospitals
• Cath Labs
• Specialty Clinics
• Diagnostic Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Angioplasty Balloons Market, By Type

• 5.1 Introduction
• 5.2 Drug Eluting Balloons
• 5.3 Normal Balloons
• 5.4 Cutting Balloons
• 5.5 Scoring Balloons
• 5.6 Other Types

6 Global Angioplasty Balloons Market, By Material

• 6.1 Introduction
• 6.2 Polyurethane
• 6.3 Silicone Urethane Co-Polymers
• 6.4 Nylon
• 6.5 Other Materials

7 Global Angioplasty Balloons Market, By Indication

• 7.1 Introduction
• 7.2 Angioplasty
• 7.3 Renal Artery Angioplasty
• 7.4 Peripheral Angioplasty
• 7.5 Carotid Angioplasty
• 7.6 Venous Angioplasty
• 7.7 Coronary Angioplasty
• 7.8 Other Indications

8 Global Angioplasty Balloons Market, By End User

• 8.1 Introduction
• 8.2 Ambulatory Surgical Centers
• 8.3 Hospitals
• 8.4 Cath Labs
• 8.5 Specialty Clinics
• 8.6 Diagnostic Centers
• 8.7 Other End Users

9 Global Angioplasty Balloons Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Boston Scientific Corporation
• 11.2 Medtronic
• 11.3 Johnson & Johnson Services, Inc.
• 11.4 Abbott
• 11.5 Cardinal Health
• 11.6 Terumo Medical Corporation
• 11.7 B. Braun Melsungen AG
• 11.8 ENDOCOR GmbH
• 11.9 BIOTRONIK
• 11.10 Cook
• 11.11 Spectranetics
• 11.12 C. R. Bard, Inc.
• 11.13 AngioDynamics
• 11.14 Becton Dickinson
• 11.15 Biomerics
• 11.16 INFINITY Angioplasty Balloon
• 11.17 MicroPort Scientific Corporation
• 11.18 Nipro Medical Corporation.
• 11.19 Hexacath
• 11.20 CTK biotech, Inc